Tackling PD1i resistance in Hodgkin lymphoma

Blood. 2023 Oct 19;142(16):1333-1334. doi: 10.1182/blood.2023021283.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Hodgkin Disease* / drug therapy
  • Hodgkin Disease* / pathology
  • Humans
  • Lymphoma, Non-Hodgkin*
  • Programmed Cell Death 1 Receptor
  • Vorinostat

Substances

  • pembrolizumab
  • Programmed Cell Death 1 Receptor
  • Vorinostat